Alzheimer's Disease Neurotrophin and Growth Factor Companies

Overview

Overview

Neurotrophin and growth factor therapies represent a fundamental approach to Alzheimer's disease treatment that aims to preserve and restore neuronal function through endogenous neuroprotective pathways. Unlike amyloid-targeting therapies that focus on removing pathological proteins, neurotrophin and growth factor approaches enhance the brain's intrinsic capacity for neuronal survival, synaptic plasticity, and repair.

The rationale for this approach stems from the well-documented decline of neurotrophic support in Alzheimer's disease. Key growth factors including [BDNF](/proteins/bdnf-protein), [GDNF](/proteins/gdnf-protein), [NGF](/proteins/nerve-growth-factor), and [FGF](/proteins/fgf-protein) family members are reduced in AD brains, contributing to synaptic loss, neuronal death, and cognitive decline. By delivering or enhancing these neurotrophic signals, companies in this space aim to slow or reverse disease progression through disease-modifying mechanisms.

This category covers companies developing:

• Neurotrophin delivery (BDNF, NGF, NT-3, NT-4)
• Growth factor therapies (GDNF, FGF, IGF-1, VEGF, HGF)
• Neurotrophin mimetics (small molecule agonists)
• Gene therapy approaches (AAV-mediated growth factor expression)
• Cell-based delivery (encapsulated cell implants)

Key Companies and Programs

Athira Pharma

[Athira Pharma](/companies/athira-pharma) (NASDAQ: ATHA) is a clinical-stage company developing fosgonimeton (ATH-1017), a small molecule that targets the hepatocyte growth factor (HGF) system to promote neuroprotection, regeneration, and repair.

| Attribute | Details |
|-----------|---------|
| Lead Program | Fosgonimeton (ATH-1017) |
| Mechanism | HGF/MET receptor activator |
| Indication | Alzheimer's disease |
| Stage | Phase 2/3 |
| Status | Recruiting (ACT-AD study) |

Mechanism of Action: Fosgonimeton activates the MET receptor, which promotes neuronal survival, enhances synaptic function and plasticity, supports neurogenesis, modulates neuroinflammation, and improves cerebral blood flow. The HGF/MET system is naturally involved in brain repair mechanisms and is downregulated in Alzheimer's disease.

Clinical Development:

• Phase 2 LIFT-AD study in mild-to-moderate AD
• Currently enrolling in Phase 2/3 ACT-AD confirmatory study
• Primary endpoint: ADAS-Cog13 change from baseline

Trefoil Therapeutics

[Trefoil Therapeutics](/companies/trefoil-therapeutics) is a clinical-stage biotechnology company developing engineered neurotrophic factors with improved pharmacological properties.

| Attribute | Details |
|-----------|---------|
| Headquarters | Boston, Massachusetts |
| Founded | 2021 |
| Funding | Series B ($55M, 2024) |
| Focus | Engineered neurotrophic factors |

Pipeline:

| Drug | Mechanism | Indication | Stage |
|------|-----------|------------|-------|
| TF-201 | Synaptic growth factor | Alzheimer's disease | Phase 1 (recruiting) |
| TF-202 | Neuroprotective factor | Parkinson's disease | Preclinical |

TF-201 (Lead Candidate):

• Engineered neurotrophic factor designed to promote synaptic formation and function
• Promotes synaptic growth and maintenance
• Protects against glutamate-induced excitotoxic cell death
• Supports development of new neuronal circuits

• Improved half-life (extended duration of action)
• Enhanced brain penetration
• Reduced immunogenicity
• Improved stability

Neurotrope BioScience

[Neurotrope BioScience](/companies/neurotrope) (NASDAQ: NTRP) is a clinical-stage biopharmaceutical company focused on developing bryostatin, a protein kinase C (PKC) activator, for Alzheimer's disease.

| Attribute | Details |
|-----------|---------|
| Lead Program | Bryostatin-1 |
| Mechanism | PKC epsilon activator |
| Indication | Alzheimer's disease |
| Stage | Phase 2 |
| Ticker | NTRP (NASDAQ) |

Mechanism of Action:

• PKC ε activation promotes synaptic repair and formation
• Enhances long-term potentiation (LTP)
• Protects against amyloid-beta toxicity
• Promotes neurotrophic factor expression

• Multiple Phase 2 trials conducted in moderate-to-severe AD
• Showed cognitive stabilization in some patient subpopulations
• Challenges include intravenous administration and dose optimization

Teitur Trophics

[Teitur Trophics](/companies/teitur-trophics) is a biotechnology company focused on developing neurotrophic factor therapies for neurodegenerative diseases.

| Attribute | Details |
|-----------|---------|
| Focus | Neurotrophic factors, AD, PD |
| Stage | Preclinical/Discovery |
| Status | Private |

Pipeline:

| Drug | Mechanism | Indication | Stage |
|------|-----------|------------|-------|
| TT-101 | BDNF receptor agonist | Alzheimer's disease | Preclinical |
| TT-102 | GDNF analog | Parkinson's disease | Discovery |
| TT-103 | Neuroprotective peptide | Neurodegeneration | Discovery |

TT-101 (BDNF Receptor Agonist):

• Small molecule TrkB agonist
• Targets TrkB receptor (BDNF receptor)
• Promotes synaptic plasticity and neuronal survival

Synaptic Therapeutics

[Synaptic Therapeutics](/companies/synaptic-therapeutics) is a clinical-stage biotechnology company focused on protecting and restoring synaptic function in neurodegenerative diseases.

| Attribute | Details |
|-----------|---------|
| Headquarters | Cambridge, Massachusetts |
| Founded | 2021 |
| Funding | Series B ($60M, 2025) |

Pipeline:

| Drug | Mechanism | Indication | Stage |
|------|-----------|------------|-------|
| ST-101 | Sigma-2 receptor agonist | Alzheimer's disease | Phase 1 (active) |
| ST-202 | Sigma-2 receptor agonist | Parkinson's disease | Preclinical |

Mechanism: While not a direct neurotrophin, ST-101 protects synapses through sigma-2 receptor modulation, which activates stress protective pathways and prevents amyloid-beta induced synapse damage. The company focuses on downstream synaptic protection rather than upstream amyloid reduction.

Additional Companies in Development

Large Pharma Programs

| Company | Program | Mechanism | Stage |
|---------|---------|-----------|-------|
| AbbVie | -- | TrkB agonist | Preclinical |
| Takeda | -- | GDNF analog | Preclinical |
| Lilly | -- | Neurotrophic modulators | Discovery |

Emerging Biotech

• Neurogenerative: Discontinued GDNF program
• Various academic spinouts: FGF variants, BDNF delivery systems
• Cell therapy companies: Encapsulated cell delivery approaches

Mechanism Categories

1. Neurotrophin Receptor Agonists

Neurotrophins (BDNF, NGF, NT-3, NT-4) signal through Trk receptor family. Small molecule agonists aim to activate these receptors without the delivery challenges of protein therapeutics.

| Target | Function | Companies |
|--------|----------|-----------|
| TrkB | BDNF receptor | Teitur Trophics, AbbVie |
| TrkA | NGF receptor | Various |
| TrkC | NT-3 receptor | Research stage |

2. GDNF Family Ligands

The GDNF family (GDNF, neurturin, artemin, persephin) signals through GFRα/Ret receptor complex and is particularly important for neuronal survival.

| Factor | Target | Companies |
|--------|--------|-----------|
| GDNF | GFRα1/Ret | Takeda, various |
| Neurturin | GFRα2/Ret | Previous trials |

3. HGF/MET Agonists

Hepatocyte growth factor signals through the MET receptor, promoting neuroprotection and synaptic plasticity.

| Target | Companies | Stage |
|--------|-----------|-------|
| HGF/MET | Athira Pharma | Phase 2/3 |

4. FGF Variants

Fibroblast growth factors promote neurogenesis and synaptic plasticity. Engineered variants aim to improve pharmacological properties.

| Company | Program | Stage |
|---------|---------|-------|
| Trefoil Therapeutics | TF-201 | Phase 1 |
| Various | FGF analogs | Preclinical |

5. PKC Activators

Protein kinase C activation promotes synaptic plasticity and neurotrophic factor expression.

| Company | Compound | Stage |
|---------|----------|-------|
| Neurotrope | Bryostatin | Phase 2 |

Clinical Trial Landscape

| Company | Drug | Phase | Mechanism | NCT Number |
|---------|------|-------|-----------|------------|
| Athira Pharma | Fosgonimeton | Phase 2/3 | HGF/Met | NCT04466921 |
| Trefoil Therapeutics | TF-201 | Phase 1 | FGF variant | TBD |
| Neurotrope | Bryostatin | Phase 2 | PKC activator | NCT04594060 |
| Synaptic Therapeutics | ST-101 | Phase 1 | Sigma-2 | TBD |

Delivery Challenges and Solutions

Blood-Brain Barrier Penetration

The primary challenge for growth factor therapy is delivering sufficient concentrations to the CNS. Current approaches include:

| Strategy | Description | Companies |
|----------|-------------|-----------|
| AAV gene therapy | Viral vector-mediated expression | Various |
| Focused ultrasound | Temporary BBB opening | Research |
| Small molecule agonists | BBB-penetrant compounds | Athira, Teitur |
| Encapsulated cells | Cell-based delivery | Research |

Protein vs. Small Molecule

| Approach | Advantages | Challenges |
|----------|------------|-----------|
| Protein delivery | Native sequence, high potency | BBB penetration, stability |
| Gene therapy | Sustained expression | Immune response, delivery |
| Small molecules | BBB penetration, oral dosing | Receptor selectivity |

Scientific Rationale

Neurotrophic Factor Decline in AD

Multiple neurotrophic systems are impaired in Alzheimer's disease:

• BDNF: Reduced in hippocampus and cortex, correlates with cognitive decline
• NGF: Cholinergic neuron support diminished
• GDNF: Dopaminergic and general neuronal support reduced
• HGF/MET: Signaling dysregulated

Neuroprotection Mechanisms

Growth factors provide neuroprotection through:

Advantages Over Amyloid Approaches

• Disease-modifying rather than symptomatic
• No ARIA risk (for small molecules)
• Targets downstream consequences of pathology
• Preserves existing neurons and synapses

Competitive Landscape

Comparison with Approved AD Therapies

| Approach | Mechanism | Administration | ARIA Risk |
|----------|-----------|---------------|-----------|
| Lecanemab | Anti-amyloid antibody | IV infusion | Yes |
| Donanemab | Anti-amyloid antibody | IV infusion | Yes |
| Fosgonimeton | HGF/MET agonist | Oral | No |
| Bryostatin | PKC activator | IV | No |

Market Opportunity

• Approximately 6.5 million Americans with AD
• Significant unmet need for disease-modifying therapies
• Premium pricing potential for successful treatments
• Combination potential with existing therapies

Cross-Links

Related Therapeutic Pages

• [Growth Factor Therapies](/therapeutics/growth-factor-therapies)
• [BDNF Therapies](/therapeutics/bdnf-therapies)
• [Neurotrophic Factor Therapies](/therapeutics/neurotrophic-factor-therapies)
• [Gene Therapy for Neurodegeneration](/therapeutics/gene-therapy-neurodegeneration)

Related Mechanism Pages

• [Neurotrophic Signaling Pathway](/mechanisms/neurotrophic-signaling-pathway)
• [BDNF in Neurodegeneration](/mechanisms/bdnf-neurodegeneration)
• [Synaptic Plasticity Deficits](/mechanisms/synaptic-plasticity-deficits)
• [Neurotrophic Factor Decline](/mechanisms/neurotrophic-factor-decline)

Related Disease Pages

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Alzheimer's Disease Treatments](/therapeutics/alzheimers-disease-treatments)

Related Company Categories

• [AD Synaptic Repair Companies](/companies/ad-synaptic-repair-neuroprotection-companies)
• [AD Pipeline Companies](/companies/ad-pipeline-companies)
• [AD Epigenetic/Metabolic Therapy Companies](/companies/ad-epigenetic-metabolic-therapy-companies)

References

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Neurodegeneration Mechanisms](/mechanisms/neurodegeneration-common-mechanisms)
• [Clinical Trials in Alzheimer's Disease](/clinical-trials/alzheimers-disease-trials)
• [BDNF Protein](/proteins/bdnf-protein)
• [GDNF Protein](/proteins/gdnf-protein)
• [NGF Protein](/proteins/nerve-growth-factor)